Objective: In a real-world setting, we characterized demographics and early outcomes in MS patients treated with CladribineBackground: Cladribine is a recent addition to MS therapeutics and its real-world use has not been characterizedDesign/Methods: Secondary data analysis of MSBase Registry data ...
The effect of pregnancy on relapse rate and disability progression in MS: Results from the MSBase RegistryCEMO:NeurochimieHughes, S.ESpelman, TGray, O.MBoz, CVan Pesch, Vincent
The MSBase Registry contained 11,108 MS patient records from patients that had been prospectively followed between 1996 and 2010 and who fulfilled our selection criteria. A total of 2098 patients were excluded from analysis; 1372 of them had diagnosis of CIS; 726 had missing EDSS or date of ED...
In 2016, the MSBase registry presented an algorithm that enabled the diagnosis of secondary progressive multiple sclerosis (SPMS) more than three years earlier compared to diagnosis by neurologists. This work aimed to test whether this approach is equally effective in a real-world cohort of MS ...
Over the last decade, clinical registries have significantly contributed to the pool of evidence that supports management decisions in patients with multiple sclerosis. Being the largest international registry of multiple sclerosis and neuroimmunological disorders, MSBase collects demographic, clinical and ...
formation of cord lesions more effectively than lDMTs.Patients with relapse-onset MS, a cord magnetic resonance imaging (MRI) within 6 months before/after initiation of their first DMT and ≥1 cord MRI at follow-up (interval > 6 months) were extracted from the MSBase registry (ACTRN...
P. DuquetteHopital Hotel-Dieu de LevisNeurology AsiaOM Gray, D Jolly , C Zwanikken C, et al .Temporal variation of onset of relapses in multiple sclerosis is not seasonal: results from the MSBase registry.Neurology Asia,(13), 2008,199-200....
A cost-effectiveness analysis using real-world data from the MSBase registry: comparing natalizumab to fingolimod in patients with inadequate response to diseasemodifying therapies in relapsing-remitting multiple sclerosis (RRMS) in Scotland (P1.364)...
Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy.doi:10.1177/1352458520921087Nathaniel LizakSuzanne HodgkinsonErnest ButlerJeannette Lechner-ScottMark SleePamela Ann McCombeCameron Shaw
0488 The MSBase global web registry: joining independent local patient databases for multi-centre researchdoi:10.1016/S0022-510X(05)80856-1ELSEVIERJournal of the Neurological Sciences